{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:12:00Z","timestamp":1780405920450,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82170193"],"award-info":[{"award-number":["82170193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82200215"],"award-info":[{"award-number":["82200215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82170193"],"award-info":[{"award-number":["82170193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Health Science and Technology Project","award":["TJWJ2022XK021"],"award-info":[{"award-number":["TJWJ2022XK021"]}]},{"name":"Tianjin Health Science and Technology Project","award":["TJWJ2022XK021"],"award-info":[{"award-number":["TJWJ2022XK021"]}]},{"name":"Tianjin Health Research Project","award":["TJSQNYXXR-D2-152"],"award-info":[{"award-number":["TJSQNYXXR-D2-152"]}]},{"name":"Tianjin Health Research Project","award":["TJSQNYXXR-D2-152"],"award-info":[{"award-number":["TJSQNYXXR-D2-152"]}]},{"name":"the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2022-I2M-1-022"],"award-info":[{"award-number":["2022-I2M-1-022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06246-9","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:57:34Z","timestamp":1740477454000},"page":"1845-1856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongchao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"6246_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms [J]. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"7","key":"6246_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","volume":"83","author":"R Rimokh","year":"1994","unstructured":"Rimokh R, Berger F, Delsol G et al (1994) Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas [J]. Blood 83(7):1871\u20131875","journal-title":"Blood"},{"issue":"5","key":"6246_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments [J]. Am J Hematol 97(5):638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"issue":"26","key":"6246_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL (2022) Mantle-Cell lymphoma [J]. N Engl J Med 386(26):2495\u20132506. https:\/\/doi.org\/10.1056\/NEJMra2202672","journal-title":"N Engl J Med"},{"issue":"6","key":"6246_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/jco.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D et al (2019) Survival outcomes of younger patients with Mantle Cell Lymphoma Treated in the Rituximab era [J]. J Clin Oncol 37(6):471\u2013480. https:\/\/doi.org\/10.1200\/jco.18.00690","journal-title":"J Clin Oncol"},{"issue":"3","key":"6246_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3324\/haematol.2021.279037","volume":"107","author":"A Albertsson-Lindblad","year":"2022","unstructured":"Albertsson-Lindblad A, Palsdottir T, Smedby KE et al (2022) Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007\u20132017 [J]. Haematologica 107(3):740\u2013743. https:\/\/doi.org\/10.3324\/haematol.2021.279037","journal-title":"Haematologica"},{"key":"6246_CR7","doi-asserted-by":"publisher","unstructured":"Yi S, Yan Y, Jin M et al (2022) Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma [J]. J Clin Invest 132(3). https:\/\/doi.org\/10.1172\/jci153283","DOI":"10.1172\/jci153283"},{"issue":"Suppl 1","key":"6246_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.3149","volume":"41","author":"E Silkenstedt","year":"2023","unstructured":"Silkenstedt E, Dreyling M (2023) Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches [J]. Hematol Oncol 41(Suppl 1):36\u201342. https:\/\/doi.org\/10.1002\/hon.3149","journal-title":"Hematol Oncol"},{"issue":"16","key":"6246_CR9","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study [J]. Blood 115(16):3215\u20133223. https:\/\/doi.org\/10.1182\/blood-2009-06-230250","journal-title":"Blood"},{"issue":"1","key":"6246_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3324\/haematol.2018.191429","volume":"104","author":"R Gressin","year":"2019","unstructured":"Gressin R, Daguindau N, Tempescul A et al (2019) A phase 2 study of Rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma [J]. Haematologica 104(1):138\u2013146. https:\/\/doi.org\/10.3324\/haematol.2018.191429","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"6246_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2020-140457","volume":"136","author":"MB Callanan","year":"2020","unstructured":"Callanan MB, Macintyre E, Delfau-Larue M-H et al (2020) Predictive Power of Early, sequential MRD monitoring in peripheral blood and bone marrow in patients with Mantle Cell Lymphoma following autologous stem cell transplantation with or without Rituximab Maintenance; final results from the LyMa-MRD project, conducted on Behalf of the Lysa Group [J]. Blood 136(Supplement 1):12\u201313. https:\/\/doi.org\/10.1182\/blood-2020-140457","journal-title":"Blood"},{"issue":"12","key":"6246_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1182\/blood.2021014270","volume":"140","author":"S Ferrero","year":"2022","unstructured":"Ferrero S, Grimaldi D, Genuardi E et al (2022) Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma [J]. Blood 140(12):1378\u20131389. https:\/\/doi.org\/10.1182\/blood.2021014270","journal-title":"Blood"},{"issue":"3","key":"6246_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","volume":"23","author":"A Kolstad","year":"2017","unstructured":"Kolstad A, Pedersen LB, Eskelund CW et al (2017) Molecular monitoring after autologous stem cell transplantation and Preemptive Rituximab Treatment of Molecular Relapse; results from the Nordic Mantle Cell Lymphoma studies (MCL2 and MCL3) with median Follow-Up of 8.5 years [J]. Biol Blood Marrow Transpl 23(3):428\u2013435. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.634","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"6246_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.7150\/jca.51959","volume":"12","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Chen H, Tao Y et al (2021) Minimal residual disease and survival outcomes in patients with Mantle Cell Lymphoma: a systematic review and meta-analysis [J]. J Cancer 12(2):553\u2013561. https:\/\/doi.org\/10.7150\/jca.51959","journal-title":"J Cancer"},{"issue":"6","key":"6246_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41409-022-01655-0","volume":"57","author":"H Liu","year":"2022","unstructured":"Liu H, Liu W, Li R et al (2022) A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma [J]. Bone Marrow Transplant 57(6):1017\u20131020. https:\/\/doi.org\/10.1038\/s41409-022-01655-0","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"6246_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification [J]. J Clin Oncol 32(27):3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"24","key":"6246_CR17","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","volume":"128","author":"M Kwok","year":"2016","unstructured":"Kwok M, Rawstron AC, Varghese A et al (2016) Minimal residual disease is an independent predictor for 10-year survival in CLL [J]. Blood 128(24):2770\u20132773. https:\/\/doi.org\/10.1182\/blood-2016-05-714162","journal-title":"Blood"},{"issue":"2","key":"6246_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.14996","volume":"180","author":"ML Chase","year":"2018","unstructured":"Chase ML, Armand P (2018) Minimal residual disease in non-hodgkin lymphoma\u2013 current applications and future directions [J]. Br J Haematol 180(2):177\u2013188. https:\/\/doi.org\/10.1111\/bjh.14996","journal-title":"Br J Haematol"},{"issue":"5","key":"6246_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hon.2550","volume":"36","author":"P Klener","year":"2018","unstructured":"Klener P, Fronkova E, Kalinova M et al (2018) Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of Rituximab maintenance [J]. Hematol Oncol 36(5):773\u2013778. https:\/\/doi.org\/10.1002\/hon.2550","journal-title":"Hematol Oncol"},{"key":"6246_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00899","author":"E Hoster","year":"2023","unstructured":"Hoster E, Delfau-Larue MH, Macintyre E et al (2023) Predictive value of minimal residual disease for efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: results from the European Mantle Cell Lymphoma Elderly trial [J]. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.23.00899","journal-title":"J Clin Oncol"},{"issue":"2","key":"6246_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cyto.b.21210","volume":"88","author":"J Chovancov\u00e1","year":"2015","unstructured":"Chovancov\u00e1 J, Bernard T, Stehl\u00edkov\u00e1 O et al (2015) Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach [J]. Cytometry B Clin Cytom 88(2):92\u2013100. https:\/\/doi.org\/10.1002\/cyto.b.21210","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"6246_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A et al (2016) Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study [J]. Haematologica 101(3):336\u2013345. https:\/\/doi.org\/10.3324\/haematol.2015.134957","journal-title":"Haematologica"},{"issue":"1","key":"6246_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","volume":"13","author":"D Jung","year":"2020","unstructured":"Jung D, Jain P, Yao Y et al (2020) Advances in the assessment of minimal residual disease in mantle cell lymphoma [J]. J Hematol Oncol 13(1):127. https:\/\/doi.org\/10.1186\/s13045-020-00961-8","journal-title":"J Hematol Oncol"},{"issue":"10044","key":"6246_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J et al (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network [J]. Lancet 388(10044):565\u2013575. https:\/\/doi.org\/10.1016\/S0140-6736(16)00739-X","journal-title":"Lancet"},{"issue":"4","key":"6246_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3324\/haematol.11267","volume":"93","author":"S B\u00f6ttcher","year":"2008","unstructured":"B\u00f6ttcher S, Ritgen M, Buske S et al (2008) Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations [J]. Haematologica 93(4):551. https:\/\/doi.org\/10.3324\/haematol.11267","journal-title":"Haematologica"},{"issue":"Supplement1","key":"6246_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood-2019-129323","volume":"134","author":"M Smith","year":"2019","unstructured":"Smith M, Jegede O, Parekh S et al (2019) Minimal residual Disease (MRD) Assessment in the ECOG1411 randomized phase 2 trial of Front-Line Bendamustine-Rituximab (BR)-Based induction followed by Rituximab (R)\u2009\u00b1\u2009Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL) [J]. Blood 134(Supplement1):751\u2013. https:\/\/doi.org\/10.1182\/blood-2019-129323","journal-title":"Blood"},{"issue":"26","key":"6246_CR27","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M et al (2022) Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell lymphoma [J]. N Engl J Med 386(26):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa2201817","journal-title":"N Engl J Med"},{"issue":"6","key":"6246_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VH Van der Velden","year":"2003","unstructured":"Van der Velden VH, Hochhaus A, Cazzaniga G et al (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects [J]. Leukemia 17(6):1013\u20131034. https:\/\/doi.org\/10.1038\/sj.leu.2402922","journal-title":"Leukemia"},{"issue":"2","key":"6246_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1182\/blood.V89.2.724","volume":"89","author":"P Corradini","year":"1997","unstructured":"Corradini P, Astolfi M, Cherasco C et al (1997) Molecular monitoring of minimal residual disease in Follicular and Mantle Cell Non-hodgkin\u2019s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting [J]. Blood 89(2):724\u2013731. https:\/\/doi.org\/10.1182\/blood.V89.2.724","journal-title":"Blood"},{"issue":"12","key":"6246_CR30","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","volume":"12","author":"M Ladetto","year":"2006","unstructured":"Ladetto M, Magni M, Pagliano G et al (2006) Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma [J]. Biol Blood Marrow Transplant 12(12):1270\u20131276. https:\/\/doi.org\/10.1016\/j.bbmt.2006.07.007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6246_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and bone marrow transplant and autologous blood and marrow transplant registries [J]. Br J Haematol 120(5):793\u2013800. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04140.x","journal-title":"Br J Haematol"},{"issue":"19","key":"6246_CR32","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","volume":"3","author":"Y Yan","year":"2019","unstructured":"Yan Y, Mao X, Liu J et al (2019) The impact of response kinetics for multiple myeloma in the era of novel agents [J]. Blood Adv 3(19):2895\u20132904. https:\/\/doi.org\/10.1182\/bloodadvances.2019000432","journal-title":"Blood Adv"},{"issue":"3","key":"6246_CR33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Br\u00fcggemann","year":"2006","unstructured":"Br\u00fcggemann M, Raff T, Flohr T et al (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia [J]. Blood 107(3):1116\u20131123. https:\/\/doi.org\/10.1182\/blood-2005-07-2708","journal-title":"Blood"},{"issue":"12","key":"6246_CR34","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai QQ, Zhang W et al (2023) Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis [J]. Cancer Med 12(12):13204\u201313216. https:\/\/doi.org\/10.1002\/cam4.6009","journal-title":"Cancer Med"},{"key":"6246_CR35","doi-asserted-by":"publisher","unstructured":"Fenske TS (2023) Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide [J]. J Clin Oncol 41(3):452. https:\/\/doi.org\/10.1200\/jco.22.01661","DOI":"10.1200\/jco.22.01661"},{"key":"6246_CR36","unstructured":"Timothy S, Fenske M Of the Medical College of Wisconsin. Stem Cell Transplant Offers No Additional Benefit for patients with Mantle Cell Lymphoma in Deep Remission [Z]. December 10, 2024, at 7:30 a.m. Pacific time in Hall B (San Diego Convention Center)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06246-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:09:59Z","timestamp":1745575799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6246"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06246-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}